MetaVia's obesity treatment candidate 먹튀없는 바카라사이트1726 demonstrates weight loss and glycemic control in Phase 1 study

[by Yu, Suin] MetaVia, an affiliate of Dong-A ST, reported on January 6 that its Phase 1 clinical trial evaluating the maximum tolerated dose of ‘DA-1726’ (development code), a glucagon-like peptide 1 (GLP-1)/glucagon (GCG) dual agonist under development for the treatment of obesity, demonstrated excellent outcomes, including pronounced weight loss, improvements in glycemic control, and a decrease in liver stiffness.

The trial enrolled nine adults with obesity, defined by a body mass index (BMI) ranging from 30 to 45 kg/m2. Participants received once-weekly administration of either 48 mg of 먹튀없는 바카라사이트1726 or placebo over treatment periods of four and eight weeks, respectively. In the 48 mg 먹튀없는 바카라사이트1726 cohort, treatment was generally well tolerated, with only mild to moderate gastrointestinal adverse events reported and no treatment discontinuation observed. At week 4, participants achieved an average weight loss of 6.1% (6.6 kg), accompanied by a decrease in waist circumference of 5.8 cm (2.3 inches). By week 8, mean body weight reduction reached 9.1% (9.6 kg), with waist circumference reduced by 9.8 cm (3.8 inches). These findings suggest that 먹튀없는 바카라사이트1726, a dual agonist, may confer superior visceral fat-reducing effects compared with single GLP-1 receptor agonists.

Notably, by day 54 of treatment, fasting plasma glucose levels declined from 105.3 mg/dL to 93 mg/dL, returning to the normoglycemic range. Glycated hemoglobin (HbA1c) levels also decreased from 6.0% to 5.5%, indicating a clinically meaningful improvement in glycemic control. These findings suggest that 먹튀없는 바카라사이트1726 may offer therapeutic benefits not only for obesity but also for the treatment of diabetes or prediabetes in obese individuals.

Furthermore, vibration-controlled transient elastography (VCTE), a noninvasive test for liver stiffness and a recognized biomarker in the development of therapies for metabolic dysfunction-associated steatohepatitis (MASH), demonstrated a 23.7% reduction in liver stiffness relative to the baseline showing of 5.9 kPa by day 54 following 먹튀없는 바카라사이트1726 administration. MetaVia noted that these findings provide evidence of a direct therapeutic effect of 먹튀없는 바카라사이트1726 on the liver, in addition to its metabolic benefits.

먹튀없는 바카라사이트1726 is a novel drug candidate belonging to the oxyntomodulin analog class of anti-obesity therapeutics currently under development. The compound exerts dual agonistic activity on GLP-1 and GCG receptors that promotes appetite suppression, stimulates insulin secretion, and increases peripheral basal energy metabolic rates, ultimately leading to weight loss and improvement in glycemic control.

Based on the favorable weight loss effects and tolerability profile demonstrated in this additional Phase 1 clinical trial, MetaVia plans to initiate an additional 16-week dose-escalation Phase 1 clinical trial. In this study, the first stage will increase the dose to 48 mg of 먹튀없는 바카라사이트1726, followed by a second stage increasing the dose to 64 mg.

“Through this additional Phase 1 clinical study, DA-1726 has once again demonstrated its excellent weight-loss efficacy, while also confirming clinically meaningful effects on glycemic reduction and liver stiffness improvement,” said Kim Hyung-heon, CEO of MetaVia. “With the upcoming 16-week clinical trial, we aim to further solidify the therapeutic potential and competitiveness as a next-generation treatment for obesity,” he added.